Study to Evaluate the Relative Abuse Potential of Almorexant in Recreational Drug Users
Phase 1
Completed
- Conditions
- Abuse Potential Study
- Interventions
- First Posted Date
- 2013-11-19
- Last Posted Date
- 2016-02-12
- Lead Sponsor
- Midnight Pharma, LLC
- Target Recruit Count
- 42
- Registration Number
- NCT01987739
Almorexant in Primary Insomnia
- First Posted Date
- 2008-03-21
- Last Posted Date
- 2016-02-12
- Lead Sponsor
- Midnight Pharma, LLC
- Target Recruit Count
- 161
- Registration Number
- NCT00640848
- Locations
- ๐ฆ๐น
The Siesta Group, Vienna, Austria
๐ฆ๐นMedical University of Vienna, University Clinic of Psychiatrie, Vienna, Austria
๐ซ๐ฎSkogby Sleep Clinic, Espoo, Finland
Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Midnight Pharma, LLC
- Target Recruit Count
- 709
- Registration Number
- NCT00608985
- Locations
- ๐ฆ๐บ
The Woolcock Institute of Medical Research, Glebe, Australia
๐ฆ๐บAustralian Clinical Research Organisation, Kippa Ring, Australia
๐ฆ๐บMelbourne Sleep Disorder Centre, Melbourne, Australia
Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia
Phase 2
Completed
- Conditions
- Chronic Primary Insomnia
- Interventions
- Drug: ACT-078573 and matching placeboDrug: ACT-078573 oral capsules at 25 and 100 mg and matching placebo
- First Posted Date
- 2008-02-04
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Midnight Pharma, LLC
- Target Recruit Count
- 112
- Registration Number
- NCT00606593
- Locations
- ๐บ๐ธ
Sleep Medicine Associates P.A., Dallas, Texas, United States
๐บ๐ธPAB Clinical Research, Brandon, Florida, United States
๐บ๐ธOmniTrials, Naples, Florida, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath